Evidence map›Paper›PMID 42052448›Full record

ArticleFrontiers in oncology2026

Chronic myeloid leukemia in blast phase masquerading as T-lymphoblastic lymphoma with t(22;22) karyotype: a case report.

Yang Liu, Zhengdong Hao, Jun Bai, Wen Zhou, Hongbin Zhang, Zhiyuan Guan, Liansheng Zhang, Lijuan Li

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang LiuDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Zhengdong HaoDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Jun BaiKey Laboratory of the Hematology of Gansu Province, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Wen ZhouDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Hongbin ZhangDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Zhiyuan GuanDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Liansheng ZhangDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Lijuan LiDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article reports a rare case of chronic myeloid leukemia (CML) in blast phase presenting clinically as T-lymphoblastic lymphoma (T-LBL). A 56-year-old male was admitted due to cervical masses, and lymph node biopsy initially diagnosed T-LBL. Subsequent bone marrow examination revealed positivity for the BCR::ABL1 (P210) fusion gene. Flow cytometry (FCM) and immunohistochemistry (IHC) confirmed that the tumor cells co-expressed T-lymphoid and myeloid antigens, and fluorescence

Indexed as

BCR::ABL1 fusion geneblast phase chronic myeloid leukemiacomplex karyotypemixed phenotypeT-lymphoblastic lymphomatyrosine kinase inhibitor

Identifiers

PMID42052448
PMCPMC13111088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.